MedImmune reports earnings

MEDI reported a second quarter loss per share of $0.18, beating the consensus estimate of a loss of $0.20. In the same period last year, MEDI's loss was $0.12, which excludes charges associated with its terminated FluMist deal with Wyeth (WYE). MEDI's sales are seasonal, and the company is profitable on a full year basis. ...